67-73-2 (醋酸氟轻松,Fluocinolone Acetonide)

醋酸氟轻松;肤轻松;氟轻松;仙乃乐;醋酸肤轻松;氟氢松;2-苯并呋喃甲醇胺;醋酸肤轻松 USP标准品;醋酸氟轻松 CP;醋酸氟轻松标准品(JP);肤轻松醋酸酯;氟轻松原药;氟西奈德;乙酸肤轻松;游离肤轻松;游离氟轻松;11b-羟基-16a,17-[(1-甲基亚乙基)-双(氧)]-21-(乙酰氧基)-6a,9-二氟孕甾-1,4-二烯-3,20-二酮;醋酸氟轻松,氟轻松(肤轻松);酮;6α,9α-二氟-11β,16α,17α,21-四羟基-1,4-妊娠双烯-3,20-二酮;6α,9α-二氟-16α-羟基泼尼松龙16,17-缩丙酮;6α-氟代曲安奈德;

Fluocinolone Acetonide;Ethyl O-mesitylsulfonylacetohydroxamate;Fluocinoloe Acetonide;Fluocinolone (Acetonide);6α,9α-Difluoro-11β,16α,17α,21-tetrahydroxy-1,4-pregnadiene-3,20-dione;Fluocinonide;6a,9a-Fifluoro-16a,17a-isopropylidenedioxy-1,4-pregnadiene-3,20-dione;Fluocinolone;Synalar;Flucinar;Synandone;Synemol;Synamol;Fluonid;Jellin;Coriphate;Synandrone;Flupollon;Percutina;Fluovitif;Tefunote;Synotic;Sinalar;Radiocin;Omniderm;Dermalar;Localyn;Synsac;Fluotrex;Synalar-HP;Retisert;Fluocet;Localyn Syntex;Derma-smoothe/fs;Cortiplastol;Prodermin;Fluocinolonacetonidum;Flucort;Fluocinolone 16,17-acetonide;Iluvien;Capex;Neo-Synalar;Fs Shampoo;Fluocinoloni acetonidum;Acetonide de fluocinolone;Fluocinolone acetonide [DCIT];Dermatin (steroid);6alpha;UNII-0CD5FD6S2M;CAS-67-73-2;Tox21_110869_1;HMS2090I14;Fluocinolone acetonide [USAN:INN:JAN];FEBLZLNTKCEFIT-VSXGLTOVSA-N;F0657;FLUOCINOLONE ACETONIDE COMPONENT OF ILUVIEN;FLUOCINOLONE ACETONIDE [INN];Fluocinolone acetonide, European Pharmacopoeia (EP) Reference Standard;EINECS 200-668-5;Fluocinolone acetonide [USAN:USP:INN:JAN];FLUOCINOLONE ACETONIDE [GREEN BOOK];RS-1401 AT;Fluocinolone acetonide; 6?,9-Difluoro-11?,21-dihydroxy-16?,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione;YUTIQ;Fluocinolide (acetate);SR-01000000109;NCGC00255654-01;ydroxyprednisolone 16,17-acetonide;FLUOCINOLONE ACETONIDE [HSDB];Tox21_302364;SR-01000000109-2;SMR000058329;CCG-221165;Fluocinolone acetonide (JP17/USP/INN);D01825;WLN: T F5 E5 B666 GO IO RV AHTTTT&J A BF CQ E FVIQ H H OF -A&BHO -B&ACEF;Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone (8CI);CHEBI:31623;67-73-2;FLUOCINOLONE ACETONIDE COMPONENT OF NEO-SYNALAR;Opera_ID_1295;Fluocinolone acetonide intravitreal implant;6.Alpha.,9-Difluoro;Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)-, (6.alpha.,11.beta.,16.alpha.)-;Acetonida de fluocinolona;6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone;FLUOCINOLONE ACETONIDE COMPONENT OF OTOVEL;Dermatin;6.alpha.,9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide;NSC-92339;FLUOCINOLONE ACETONIDE [USP IMPURITY];Fluocinolone acetonide (Flucort-N);NEO-SYNALAR COMPONENT FLUOCINOLONE ACETONIDE;FLUOCINOLONE ACETONIDE [JAN];6.alpha.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone;Fluortriamcinolone Acetonide;(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one;DTXSID0040674;(6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione;FLUOCINOLONE ACETONIDE [USP MONOGRAPH];FLUOCINOLONE ACETONIDE [ORANGE BOOK];difluoro-hydroxy-(2-hydroxyacetyl)-tetramethyl-[?]one;AS-13690;HSDB 3083;NC00562;Fluocinolone acetonide for system suitability;FLUOCINOLONE ACETONIDE [USP-RS];D02QJH;AC1069;Retisert (TN);Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-;FLUOCINOLONE ACETONIDE [MI];Acetonide de fluocinolone [INN-French];HMS2230D13;FLUOCINOLONE ACETONIDE [MART.];6alpha,9alpha-Difluoro-16alpha-hydroxyprednisolone 16,17-acetonide;Fluocinoloni acetonidum [INN-Latin];NSC 92339;0CD5FD6S2M;DB00591;MFCD00010525;6.alpha.,17-acetonide;(6a,11b,16a)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-pregna-1,4-diene-3,20-dione;Pregna-1,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-;Fluocinolone acetonide, United States Pharmacopeia (USP) Reference Standard;Fluocinoloneacetonide;AKOS015963144;Fluocinolone acetonide for system suitability, European Pharmacopoeia (EP) Reference Standard;C24H30F2O6;Fluocinolone acetonide (JP15/USP/INN);Q924467;EN300-7410632;LS-118443;CCRIS 3250;HMS3259G12;Fluocet (TN);Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone;6.alpha.,9-Difluoro-11.beta.,16.alpha.,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone;6.Alpha., 9.alpha.-Difluoro-16.alpha.-h;Fluocinolone Acetonide (anti-inflammatory);Oto-synalar;AB00383017_11;CHEMBL989;s2470;NCGC00021301-04;fluocinolone-acetonide;DTXCID8020674;Pregna-1,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-;BF176452;Pregna-1,4-diene-3,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone;(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-5-hydroxy-6b-(hydroxyacetyl)-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one;ILUVIEN COMPONENT FLUOCINOLONE ACETONIDE;MLS000028545;(6alpha,9alpha,11beta,16beta)-6,9-Difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]pregna-1,4-diene-3,20-dione;Flucort-N;BRD-K94353609-001-21-6;acetonido de fluocinolona;FLUOCINOLONE ACETONIDE [WHO-DD];TRI-LUMA COMPONENT FLUOCINOLONE ACETONIDE;Fluocinolone acetonide - BP;Dermotic;Pregna-1,20-dione, 6.alpha.,9-difluoro-11.beta.,16.alpha.,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone;A853087;AC-429;Medidur;OTOVEL COMPONENT FLUOCINOLONE ACETONIDE;NSC92339;Flucinolone acetonide;HY-B0415;Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,12-dihydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6-alpha,11-beta,16-alpha)-;component of Neo-Synalar;Fluocinolone acetonide for peak identification, European Pharmacopoeia (EP) Reference Standard;4b,12-Difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-2-one;Flucort-N (TN);RS 1401AT;FLUOCINOLONE ACETONIDE [USAN];Fluocinolone Acetonide, Pharmaceutical Secondary Standard; Certified Reference Material;Pregna-1,4-diene-3,20-dione, 6,9-difluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis(oxy)]-, (6.alpha.,11.beta.,16.alpha.)-;Fluocinolonacetonid;flucinolone;NCI60_042042;6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione 16,17-Acetonide;6a,9a-difluoro-16a-hydroxyprednisolone 16,17-acetonide;FLUOCINOLONE ACETONIDE COMPONENT OF TRI-LUMA;(2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-8b-(2-hydroxyacetyl)-6a,8a,10,10-tetramethyl-6a,6b,7,8,8a,8b,11a,12,12a,12b-decahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-4(2H)-one;6alpha,9alpha-Difluoro-11beta,16alpha,17alpha,21-tetrahydroxy-1,4-pregnadiene-3,20-dione;Tox21_110869;GTPL7077;AB00383017-10;Fluzon [Steroid];Fluocinolone acetonide, analytical standard;OTOVEL COMPONENT OF FLUOCINOLONE ACETONIDE;MLS001076276;FLUOCINOLONE ACETONIDE [EP MONOGRAPH];Acetonida de fluocinolona [INN-Spanish];FLUOCINOLONE ACETONIDE [VANDF];NCGC00021301-06;PREGNA-1,4-DIENE-3,20-DIONE, 6,9-DIFLUORO-11,21-DIHYDROXY-16,17-((1-METHYLETHYLIDENE)BIS(OXY))-, (6.ALPHA.,11.BETA.,16.ALPHA.)-;6alpha-Fluorotriamcinolone acetonide;(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-16-one;Synalar (TN);6-alpha,9-alpha-Difluoro-16-alpha-hydroxyprednisolone 16,17-acetonide;6.alpha.-Fluorotriamcinolone acetonide;HMS3715J11;W-104704;SCHEMBL4795;6.alpha., 9.alpha.-Difluoro-16.alpha.-hydroxyprednisolone 16,17-acetonide;Acetonide, Fluocinolone;Fluocinolone Acetonide Topical;Acetonide de fluocinolone (INN-French);Synalar Solution Veterinary;Synalar Cream Veterinary;Fluocinolone acetonide (USAN:USP:INN:JAN);S01BA15;Fluocinolone Acetonide Oil, 0.01% (Ear Drops);6alpha,9-Difluoro-11beta,21-dihydroxy-16alpha,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione;Fluzon;Fluocinolone Acetonide 0.01%;(4aS,4bR,5S,6aS,6bS,9aR,10aS,10bS,12S)-4b,12-difluoro-6b-glycoloyl-5-hydroxy-4a,6a,8,8-tetramethyl-4a,4b,5,6,6a,6b,9a,10,10a,10b,11,12-dodecahydro-2H-naphtho(2',1':4,5)indeno(1,2-d)(1,3)dioxol-2-one;Fluocinolon acetonid;fluocinolone (alcohol);S02BA08;C05AA10;D07AC04;XILAPAK;Acetonide, Fluortriamcinolone;FLUOCINONIDE ACETONIDE;FLUOCINOLONE ACETONIDE (USP MONOGRAPH);FLUOCINOLONE ACETONIDE (USP-RS);FLUOCINOLONE ACETONIDE (MART.);Fluzon (Steroid);Acetonida de fluocinolona (INN-Spanish);Synalar Ts;FLUOCINOLONE ACETONIDE (USP IMPURITY);NS00008944;Flac Otic Oil;FLAC;Fluocinolone Acetonide Topical Solution USP, 0.01%;Fluocinoloni acetonidum (INN-Latin);(6alpha,11beta,16alpha)-6,9-Difluoro-11,21-dihydroxy-16,17-((1-methylethylidene)bis(oxy))pregna-1,4-diene-3,20-dione;FLUOCINOLONE ACETONIDE (EP MONOGRAPH);Fluocinolone AcetonideOil;(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-6,6,9,13-tetramethyl-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one;Fluocinolone acetonide; 6a,9-Difluoro-11ss,21-dihydroxy-16a,17-(1-methylethylidenedioxy)pregna-1,4-diene-3,20-dione;Fluocinolone (Acetonide) (Standard);FF15770;200-668-5;6?-Fluorotriamcinolone acetonide;HY-B0415R;

MFCD00010525

FEBLZLNTKCEFIT-VSXGLTOVSA-N

1S/C24H30F2O6/c1-20(2)31-19-9-13-14-8-16(25)15-7-12(28)5-6-21(15,3)23(14,26)17(29)10-22(13,4)24(19,32-20)18(30)11-27/h5-7,13-14,16-17,19,27,29H,8-11H2,1-4H3/t13-,14-,16-,17-,19+,21-,22-,23-,24+/m0/s1

F[C@@]12[C@]3(C=CC(C=C3[C@H](C[C@H]1[C@@H]1C[C@@H]3[C@](C(CO)=O)([C@@]1(C)C[C@@H]2O)OC(C)(C)O3)F)=O)C

200-668-5

2937210000